ENTITY
Lonza Group AG

Lonza Group AG (LONN VX)

37
Analysis
Health Care • Switzerland
Lonza Group AG produces organic fine chemicals, biocides, active ingredients, and biotechnology products. The Company offers custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing, and agricultural products industries. Lonza operates production sites in Europe, the United States, and China.
more
bullish•Novotech Holdings
•08 Sep 2021 18:48

Novotech Health IPO: Valuation First-Look

Novotech is pre-marketing an HKEx IPO to raise $0.5-1.0 billion. In this note, we present our forecasts and take the first look at Novotech's...

Logo
385 Views
Share
bullish•Abbott India
•12 Jul 2021 08:26

Global Equity Strategy: Mixed Market Environment Continues As Yields Break Down

The Hang Seng, EURO STOXX 50, MSCI ACWI ex-US, and MSCI EAFE display bearish short-term inflections and 10-year yields in the US and Germany are...

Logo
302 Views
Share
bullish•CK Asset Holdings
•10 Jun 2021 09:11

Global Equity Strategy: Opportunities In Real Estate and Health Care

The weight of the evidence continues to support our mixed, but overall constructive outlook. We outline the basis for our outlook and also...

Logo
272 Views
Share
bullish•SK Bioscience
•25 Feb 2021 07:47

SK Bioscience IPO - Valuation Analysis

We believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share which would represent 129% higher than...

Logo
424 Views
Share
bullish•SK Bioscience
•07 Feb 2021 02:23

SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The...

Logo
593 Views
Share
x